Our Product
Learn more about Amarin's first commercialized product
We operate or partner to make our medicine available across the globe. To report an adverse event or a product complaint, or to request information about our product, please visit our Contact Us page. VASCEPA®/VAZKEPA® (icosapent ethyl) is a prescription-only medicine. This means it can only be prescribed by a suitably qualified healthcare professional who can assess its appropriateness for individual patients. Healthcare professionals and patients are asked to report any suspected adverse reactions.
ALL-NP-00022 1/23
What To Do If You Experience Side Effects While Taking An Amarin Medicine
If you are taking a prescribed Amarin medicine and experience any side effects, you should immediately report these to your doctor, to another healthcare professional (such as a nurse or caretaker), or via the national reporting system. Please connect with us using the link below.
Our Science
Putting cardiovascular health at the forefront of disease management
Investor Relations
OUR INVESTMENT IN CARDIOVASCULAR HEALTH
Keeping our investors informed about our latest news. Click here for our investor presentations, events and financial results.
News and Media
Press Releases, News, Updates and Statements
From reports and reviews to partnerships and innovations, find out more about Amarin's latest new.
Our Partners
INTERESTED IN PARTNERING WITH AMARIN?
We work with leading commercial organizations around the world to bring our product to as many patients as possible. Click here for more information.
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
Miller M, Tokgozoglu L, Parhofer KG, et al. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022;20(8):609-625